News | February 09, 2015

Medtronic Introduces New Valve Sizes for CoreValve Evolut R System

Self-expanding TAVI valve gains CE Mark approval for 26, 29 mm versions

Corevalve, valve sizes

February 9, 2015 — Medtronic announced CE (Conformité Européene) mark for the 26 and 29 mm sizes of the CoreValve Evolut R System, a next-generation self-expanding valve for transcatheter aortic valve implantation (TAVI) providing the option to recapture and reposition the valve during procedures. The new larger valve sizes are delivered through a 14 French equivalent delivery system allowing small vessels to be accessed, and offer an extended sealing skirt intended to further promote valve sealing at the annulus.

The 23, 26 and 29 mm sizes of the CoreValve Evolut R and the CoreValve EnVeo R Delivery Catheter System are available in Europe and other countries that recognize the CE mark. It is not approved for commercial use in the United States, where it is currently undergoing clinical trials.

“The clinical experience with the Evolut R system has been exceptional. The system’s optimal positioning and delivery of the valve are essential to achieve the very best clinical results in TAVI. Evolut R’s low profile, positioning accuracy and enhanced sealing, all supported with the option to recapture and reposition during implantation, are a significant advance for transcatheter therapy,” said Ganesh Manoharan, M.D., consultant cardiologist, Royal Victoria Hospital, co-lead for the CoreValve Evolut R CE mark study slated for presentation at the 2015 American College of Cardiology (ACC) annual meeting. “Expanding the Evolut R valve size range enables physicians to bring these important advances to a much broader range of patients.”

The system is designed for first-time positioning accuracy and also offers an InLine Sheath that significantly reduces the profile to a 14 French equivalent, less than 1/5 inch; a smaller profile size provides a greater opportunity to treat patients with smaller vessels (down to 5 mm), which may minimize the risk of major vascular complications in some patients. The Evolut R valve is also anatomically designed for optimal fit and sealing, while maintaining strong hemodynamic performance.

For more information:

Related Content

Edwards Lifesciences Centera self expanding transcatheter (TAVR) valve has been approved with CE mark for use in Europe.
Feature | Heart Valve Technology | February 15, 2018
February 15, 2018 — Edwards Lifesciences Corp.
Boston Scientific Enters Investment and Acquisition Option Agreement With Millipede
News | Heart Valve Technology | January 24, 2018
Boston Scientific Corp. announced it has closed an investment and entered into an acquisition option agreement with...
Edwards LifeSciences Recalls Sapien 3 Certitude Delivery System
News | Heart Valve Technology | January 11, 2018
The U.S. Food and Drug Administration (FDA) announced that Edwards LifeSciences is recalling its Certitude Delivery...
Videos | Heart Valve Technology | January 04, 2018
Adam Greenbaum, M.D., co-director, Center for Structural Heart Disease, Henry Ford Hospital, Detroit, explains how hi
Edwards Acquires Harpoon Medical
News | Heart Valve Technology | December 07, 2017
December 7, 2017 — Edwards Lifesciences Corp.
Videos | Heart Valve Technology | November 15, 2017
Ted Feldman, M.D., MSCAI FACC FESC, director of the cardiac cath lab, Evanston Hospital, is the principal investigato
New Analyses Reinforce Hemodynamic Benefits of Evolut TAVR Platform in Intermediate-Risk Aortic Stenosis Patients
News | Heart Valve Technology | November 08, 2017
Medtronic plc recently presented new clinical research to support the positive clinical performance of the Evolut...
Videos | Heart Valve Technology | November 08, 2017
Stephen Worthley, MB, BS, Ph.D., director of cardiac catheterization, University of Adelaide, Australia, presents the
Videos | Heart Valve Technology | November 08, 2017
Philippe Genereux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute at Morris
Overlay Init